Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELU001 in advanced FRα overexpressing solid tumors
NCT05001282Phase 2Terminated
- Sponsor
- Elucida Oncology, Inc.
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- Nanoparticles, Antibody-Drug Conjugates (ADCs), Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ELU001 in ovarian cancer, endometrial cancer (EC), colorectal cancer (CRC) and 5 more, sponsored by Elucida Oncology, Inc. Primary endpoints: Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 28 days and Overall Response Rate up to 12 months. Started Sep 2021; status: terminated.
02
Drugs
ELU001
03
Conditions
ovarian cancerendometrial cancer (EC)colorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05001282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001282.